Abivax

Intangible assets: Obefazimod is first-in-class with a novel miR-124–enhancement MoA, supported by mechanistic biomarkers and extensive IP coverage that includes composition, methods of use into 2035, and manufacturing-process patents into 2037. If approved in 2027, US NCE regulatory exclusivity would likely protect into 2034 with potential pediatric extension; EU data and market exclusivities could run into the late 2030s.

These provide a meaningful but time-bound moat. Switching costs: In IBD, durable responders on a safe, convenient oral often remain on therapy, creating medium switching friction if long-term remission is robust. Network effects: none.

Cost advantage: as an oral small molecule, COGS should be structurally lower than injectable biologics, aiding gross margins, though commercial SG&A will be significant at launch. Efficient scale: manufacturing is outsourced; scale advantages depend on uptake.

Net: credible intangible moat potential contingent on regulatory success and durability data; durability risk tempers the score.